Literature DB >> 21515688

High affinity small protein inhibitors of human chymotrypsin C (CTRC) selected by phage display reveal unusual preference for P4' acidic residues.

András Szabó1, Dávid Héja, Dávid Szakács, Katalin Zboray, Katalin A Kékesi, Evette S Radisky, Miklós Sahin-Tóth, Gábor Pál.   

Abstract

Human chymotrypsin C (CTRC) is a pancreatic protease that participates in the regulation of intestinal digestive enzyme activity. Other chymotrypsins and elastases are inactive on the regulatory sites cleaved by CTRC, suggesting that CTRC recognizes unique sequence patterns. To characterize the molecular determinants underlying CTRC specificity, we selected high affinity substrate-like small protein inhibitors against CTRC from a phage library displaying variants of SGPI-2, a natural chymotrypsin inhibitor from Schistocerca gregaria. On the basis of the sequence pattern selected, we designed eight inhibitor variants in which amino acid residues in the reactive loop at P1 (Met or Leu), P2' (Leu or Asp), and P4' (Glu, Asp, or Ala) were varied. Binding experiments with CTRC revealed that (i) inhibitors with Leu at P1 bind 10-fold stronger than those with P1 Met; (ii) Asp at P2' (versus Leu) decreases affinity but increases selectivity, and (iii) Glu or Asp at P4' (versus Ala) increase affinity 10-fold. The highest affinity SGPI-2 variant (K(D) 20 pm) bound to CTRC 575-fold tighter than the parent molecule. The most selective inhibitor variant exhibited a K(D) of 110 pm and a selectivity ranging from 225- to 112,664-fold against other human chymotrypsins and elastases. Homology modeling and mutagenesis identified a cluster of basic amino acid residues (Lys(51), Arg(56), and Arg(80)) on the surface of human CTRC that interact with the P4' acidic residue of the inhibitor. The acidic preference of CTRC at P4' is unique among pancreatic proteases and might contribute to the high specificity of CTRC-mediated digestive enzyme regulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515688      PMCID: PMC3121398          DOI: 10.1074/jbc.M111.235754

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Local binding with globally distributed changes in a small protease inhibitor upon enzyme binding.

Authors:  Zoltán Gáspári; Borbála Szenthe; András Patthy; William M Westler; László Gráf; András Perczel
Journal:  FEBS J       Date:  2006-04       Impact factor: 5.542

2.  Analysis of protein processing by N-terminal proteomics reveals novel species-specific substrate determinants of granzyme B orthologs.

Authors:  Petra Van Damme; Sebastian Maurer-Stroh; Kim Plasman; Joost Van Durme; Niklaas Colaert; Evy Timmerman; Pieter-Jan De Bock; Marc Goethals; Frederic Rousseau; Joost Schymkowitz; Joël Vandekerckhove; Kris Gevaert
Journal:  Mol Cell Proteomics       Date:  2008-10-03       Impact factor: 5.911

Review 3.  Pacifastin-related peptides: structural and functional characteristics of a family of serine peptidase inhibitors.

Authors:  Bert Breugelmans; Gert Simonet; Vincent van Hoef; Sofie Van Soest; Jozef Vanden Broeck
Journal:  Peptides       Date:  2008-08-15       Impact factor: 3.750

4.  Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen.

Authors:  Zsófia Nemoda; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

5.  When the surface tells what lies beneath: combinatorial phage-display mutagenesis reveals complex networks of surface-core interactions in the pacifastin protease inhibitor family.

Authors:  Borbála Szenthe; András Patthy; Zoltán Gáspári; Adrienna Katalin Kékesi; László Gráf; Gábor Pál
Journal:  J Mol Biol       Date:  2007-04-19       Impact factor: 5.469

6.  Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y.

Authors:  Richárd Szmola; Miklós Sahin-Tóth
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-25       Impact factor: 11.205

7.  Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis.

Authors:  Emmanuelle Masson; Jian-Min Chen; Virginie Scotet; Cédric Le Maréchal; Claude Férec
Journal:  Hum Genet       Date:  2008-01-03       Impact factor: 4.132

8.  Structure of Locusta migratoria protease inhibitor 3 (LMPI-3) in complex with Fusarium oxysporum trypsin.

Authors:  Philippe Leone; Alain Roussel; Christine Kellenberger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-10-18

9.  Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis.

Authors:  Jonas Rosendahl; Heiko Witt; Richárd Szmola; Eesh Bhatia; Béla Ozsvári; Olfert Landt; Hans-Ulrich Schulz; Thomas M Gress; Roland Pfützer; Matthias Löhr; Peter Kovacs; Matthias Blüher; Michael Stumvoll; Gourdas Choudhuri; Péter Hegyi; René H M te Morsche; Joost P H Drenth; Kaspar Truninger; Milan Macek; Gero Puhl; Ulrike Witt; Hartmut Schmidt; Carsten Büning; Johann Ockenga; Andreas Kage; David Alexander Groneberg; Renate Nickel; Thomas Berg; Bertram Wiedenmann; Hans Bödeker; Volker Keim; Joachim Mössner; Niels Teich; Miklós Sahin-Tóth
Journal:  Nat Genet       Date:  2007-12-02       Impact factor: 38.330

10.  The RosettaDock server for local protein-protein docking.

Authors:  Sergey Lyskov; Jeffrey J Gray
Journal:  Nucleic Acids Res       Date:  2008-04-28       Impact factor: 16.971

View more
  23 in total

1.  Increased activation of hereditary pancreatitis-associated human cationic trypsinogen mutants in presence of chymotrypsin C.

Authors:  András Szabó; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

2.  Zymogen activation confers thermodynamic stability on a key peptide bond and protects human cationic trypsin from degradation.

Authors:  András Szabó; Evette S Radisky; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

3.  Long-range electrostatic complementarity governs substrate recognition by human chymotrypsin C, a key regulator of digestive enzyme activation.

Authors:  Jyotica Batra; András Szabó; Thomas R Caulfield; Alexei S Soares; Miklós Sahin-Tóth; Evette S Radisky
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

4.  Overlapping Specificity of Duplicated Human Pancreatic Elastase 3 Isoforms and Archetypal Porcine Elastase 1 Provides Clues to Evolution of Digestive Enzymes.

Authors:  Eszter Boros; András Szabó; Katalin Zboray; Dávid Héja; Gábor Pál; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2017-01-06       Impact factor: 5.157

5.  Asparagine-linked glycosylation of human chymotrypsin C is required for folding and secretion but not for enzyme activity.

Authors:  Melinda Bence; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2011-10-17       Impact factor: 5.542

6.  Determinants of chymotrypsin C cleavage specificity in the calcium-binding loop of human cationic trypsinogen.

Authors:  András Szabó; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2012-10-30       Impact factor: 5.542

7.  Functional effects of 13 rare PRSS1 variants presumed to cause chronic pancreatitis.

Authors:  Andrea Schnúr; Sebastian Beer; Heiko Witt; Péter Hegyi; Miklós Sahin-Tóth
Journal:  Gut       Date:  2013-03-01       Impact factor: 23.059

8.  Robust autoactivation, chymotrypsin C independence and diminished secretion define a subset of hereditary pancreatitis-associated cationic trypsinogen mutants.

Authors:  Andrea Geisz; Péter Hegyi; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2013-05-16       Impact factor: 5.542

9.  Autoactivation of mouse trypsinogens is regulated by chymotrypsin C via cleavage of the autolysis loop.

Authors:  Balázs Csaba Németh; Thomas Wartmann; Walter Halangk; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2013-06-27       Impact factor: 5.157

10.  Engineering Novel and Improved Biocatalysts by Cell Surface Display.

Authors:  Mason R Smith; Eshita Khera; Fei Wen
Journal:  Ind Eng Chem Res       Date:  2015-01-20       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.